Genmab 2014 Annual Report Copenhagen, Denmark; March 2,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Genmab 2014 Annual Report

Copenhagen, Denmark; March 2, 2015 – Genmab A/S (OMX: GEN) announced today its Annual Report for 2014.  Below is a summary from the report of business progress and financial performance for the year, and financial outlook for 2015. The full report is attached as a PDF file and can be found on the investor section of the company’s website, www.genmab.com .

2014 ACHIEVEMENTS
Business Progress

Maximize value of ofatumumab

  • Phase III relapsed CLL ofatumumab + fludarabine and cyclophosphamide data – Milestone moved to 2015
  • Phase III maintenance CLL data - Achieved
  • Phase III bulky refractory CLL ofatumumab vs physician’s choice data – Not achieved
  • Phase III relapsed DLBCL ofatumumab + chemotherapy vs rituximab + chemotherapy data – Not achieved
  • Update progress ofatumumab subcutaneous autoimmune development – Achieved

Expand pipeline

  • Progress Phase I HuMax-TF-ADC study - Achieved
  • Report progress pre-clinical ADC, DuoBody & HexaBody projects - Achieved

Next generation technologies

  • Enter new DuoBody technology collaborations - Achieved
  • Report progress DuoBody collaborations - Achieved
  • Start HexaBody technology collaborations - Achieved

Expansion Arzerra

  • CLL front line label expansion and launch - Achieved
  • Launch & reimbursement in new countries - Achieved

Fully exploit the potential of daratumumab

  • Phase I/II monotherapy mature efficacy data - Achieved
  • Phase I/II MM daratumumab + Revlimid safety & efficacy data - Achieved
  • Phase II MM monotherapy preliminary data – Achieved in February 2015
  • Phase Ib MM multiple combination data - Achieved
  • Start multiple new MM trials - Achieved
  • Progress non-MM indications - Achieved

Partnerships

  • Report progress partnered programs - Achieved
  • Enter new collaboration - Achieved

Disciplined financial management

  • Significant daratumumab milestones - Achieved
  • No significant increase in cost base - Achieved
  • Increase operating income and reduce cash burn – Achieved

Financial Performance

  • Revenue increased by DKK 186 million, 28 %, from DKK 664 million in 2013 to DKK 850 million in 2014, mainly driven by higher revenue related to our daratumumab and DuoBody collaborations with Janssen, partially offset by lower Arzerra royalties.
  • Operating expenses were reduced from DKK 594 million in 2013 to DKK 585 million in 2014.
  • Operating income improved by DKK 196 million, from DKK 69 million in 2013 to DKK 265 million in 2014.
  • 2014 year end cash position of DKK 2,661 million, compared to DKK 1,557 million as of December 31, 2013.

2015 OUTLOOK  

MDKK 2015 Guidance 2014 Actual Result
Revenue 650 – 725 850
Operating expenses (600) – (650) (585)
Reversal of GSK liability 175 -
Operating income 200 – 275 265
Cash position at end of year* 2,300 – 2,400 2,661
*Cash, cash equivalents, and marketable securities

Conference Call
Genmab will hold a conference call in English to discuss the results for the full year 2014 today, Monday, March 2, at 6.00 pm CET, 5.00 pm GMT or noon EST. The dial in numbers are:

+1 866 682 8490 (US participants) and ask for the Genmab conference call
+44 1452 555131 (international participants) and ask for the Genmab conference call

A live and archived webcast of the call and relevant slides will be available at www.genmab.com .

About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.  Founded in 1999, the company currently has one marketed antibody, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and daratumumab in late stage clinical development for multiple myeloma. Additionally Genmab has a clinical pipeline with both late and early stage programs, and an innovative pre-clinical pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody™ platform which creates effector function enhanced antibodies. Genmab's deep antibody expertise is expected to provide a stream of future product candidates.  Partnering of selected innovative product candidates and technologies is a key focus of Genmab’s strategy and the company has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com .

Contact:          
Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications

T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com . Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab ® ; the Y-shaped Genmab logo ® ; Genmab in combination with the Y-shaped Genmab logo™; the DuoBody logo™; the HexaBody logo™; HuMax ® ; HuMax-CD20 ® ; DuoBody ® ; HexaBody™ and UniBody ® . Arzerra ® is a registered trademark of the GSK group of companies.

Company Announcement no. 06
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 78

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
Simmons Clarifies Texas Loan Exposure, But Risks Remain

Updated Category News Views 50

A $45 million discrepancy is not a rounding error, and Simmons First National has every reason to swat it down hard. The bank says recent reporting overstated financing tied to a Texas multifamily development at $133 million. Its stated total is roughly $88 million, with about $44 million participated to another financial institution. For shareholders in NASDAQ:SFNC, that...

Continue Reading
Story Cannabis Bets on Neighborly Thanksgiving Outreach

Updated Category News Views 58

A frozen turkey is not a grand strategy deck, thank goodness; it is dinner for a household that might be feeling the squeeze. Story Cannabis plans to hand out 840 of them on Tuesday, Nov. 24, splitting the giveaway between Columbus and Cleveland with former Ohio State and Dallas Cowboys running back Michael Wiley joining employees and volunteers. In a cannabis business...

Continue Reading
North Richland Hills Bets on Its Visitor Momentum Now

Updated Category News Views 65

A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 0

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
Webster First Takes Aim at the Youth Money Literacy Gap

Updated Category News Views 39

Money mistakes get expensive long before anyone calls them mistakes. That is the uncomfortable point beneath Webster First Federal Credit Union CEO John Thomasian's November 20, 2026 discussion of financial literacy: plenty of young adults are entering the real financial world with a card, a loan offer, and a phone full of banking apps, but no sturdy framework for using...

Continue Reading
TOP-REAL Tests Digital Monitoring in HER2 Cancer Care

Updated Category News Views 116

A cancer treatment can be extraordinarily potent and still get derailed by what happens on an ordinary Tuesday at home. That unglamorous gap between clinic visits is the whole point of TOP-REAL, a phase II academic study presented at ESMO AI & Digital Oncology 2026. Solti and its European partners are testing whether closer digital follow-up can catch trouble early enough...

Continue Reading
Flair's New Aviation Alliance Offers Options, Not Orders

Updated Category News Views 55

Aircraft shortages have a funny way of turning vague partnerships into very useful insurance policies. Flair Airlines, Phoenix Aviation Capital and Avia Solutions Group announced a Strategic Commercial Cooperation Agreement on Nov. 19, 2026, and the sensible reading is straightforward: the Canadian value carrier wants more ways to solve capacity and operational problems...

Continue Reading
Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 13

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
Arizona's Dry Climate Puts Scalp Health Under Stress

Updated Category News Views 65

Desert weather is unforgiving, and apparently the scalp does not get a pass. In a Nov. 20, 2026 discussion, Scottsdale and Tucson hair-restoration physician Dr. Sharon A. Keene frames Arizona hair concerns around something easy to overlook: the condition of the skin beneath the hair. That is a more sensible starting point than treating every strand in the shower like it...

Continue Reading

Top 5 Most Recently Viewed Articles

Global Circuit Breaker Market Set for Growth Beyond USD 9 Billion

Updated Category News Views 207

Growing Demand for Circuit Breakers in Diverse Industries The circuit breaker market is gearing up for significant growth, projected to reach a remarkable valuation of USD 9.4 billion by 2031. This exciting expansion is largely attributed to the rising demand for electricity and the escalating need for efficient and reliable energy distribution systems. A compound annual...

Continue Reading
Investigation of MoonLake Immunotherapeutics by Law Firm

Updated Category News Views 145

Faruqi & Faruqi's Investigation on Behalf of Investors Faruqi & Faruqi, LLP is actively investigating potential claims for investors of MoonLake Immunotherapeutics (NASDAQ: MLTX). This initiative is aimed at supporting those who have experienced financial losses and educating them about their legal options. Investors affected are encouraged to reach out to the firm's...

Continue Reading
Golden Ocean Group Limited Announces Q2 2024 Results

Updated Category News Views 92

Golden Ocean Group Limited Reports Q2 2024 Financial Results Hamilton, Bermuda – Golden Ocean Group Limited (NASDAQ/OSE: GOGL), recognized as the largest publicly traded owner of large dry bulk vessels, has released its unaudited financial results for the quarter ending June 30, 2024. Financial Highlights In the second quarter of 2024, Golden Ocean achieved a net income...

Continue Reading
Georgia Dental Association Boosts Access to Teledentistry

Updated Category News Views 215

Expanding Access to Oral Health Care in Georgia Governor Signs Milestone Teledentistry Bill into Law Recently, a significant milestone for dental care was achieved with the signing of House Bill 567, aimed at enhancing access to oral health care through teledentistry. This new legislation, advanced by the Georgia Dental Association, is designed to remove barriers that...

Continue Reading
Anticipated Growth in Economic Indicators for Upcoming GDP

Updated Category News Views 132

Anticipated Growth in Economic Indicators for Upcoming GDP The second-quarter GDP report is set to reveal noteworthy developments in the U.S. economy, signaling a moderate recovery in output. Recent estimates, compiled from various nowcasts, suggest an anticipated growth of 1.7% in GDP for this period. Current Economic Outlook This projection remains steady from earlier...

Continue Reading